![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
The company plans to file next year for an accelerated clearance of its "exon-sk...
The FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. In an intere...
Federal health officials said Tuesday they are pulling back $11.4 billion in COV...
The global market for central nervous system therapies is on track to log its hi...
Late Tuesday, the Senate confirmed Johns Hopkins surgeon Marty Makary, M.D., as ...
Human medicines European public assessment report (EPAR): Samsca, tolvaptan, Dat...
Human medicines European public assessment report (EPAR): Xenpozyme, olipudase a...
A new kind of pharma-telehealth partnership has come under scrutiny over concern...
In this edition of STAT's AI Prognosis newsletter: A deeper look at how insurers...
Biotech stories you need to read, brought to you by The Readout.
Investment bankers say large pharma and biotech deals are stalling as executives...
Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit t...
And more of the essential health news stories of the day.
Toronto-based Altis Labs uses AI tool to review lung cancer CT scans to predict ...
The startup is using CRISPR tools to stop errant expression of a gene linked to ...
Human medicines European public assessment report (EPAR): Nyxoid, naloxone, Date...
Human medicines European public assessment report (EPAR): Cyramza, ramucirumab, ...
Cyramza-H-C-2829-P46-0010 : EPAR - Assessment report
Human medicines European public assessment report (EPAR): Alofisel, darvadstroce...